Binds A Bacterium Or Similar Microorganism Or Component Or Product Thereof (e.g., Streptococcus, Legionella, Mycoplasma, Bacterium Associated Antigen, Exotoxin, Etc.) Patents (Class 435/340)
-
Patent number: 9435805Abstract: The present invention is directed to a method for the ultrasensitive detection of beta hemolytic Streptococcus, a bacterium implicated in strep throat, using a specific protease marker. Also disclosed is a device as well as a biosensor, both of which are useful for the detection of beta hemolytic Streptococcus. The biosensor and the device can be used in conjunction with other reagents as part of a kit for detecting strep throat.Type: GrantFiled: September 22, 2011Date of Patent: September 6, 2016Assignee: Woundchek Laboratories (US), Inc.Inventors: Mitchell C. Sanders, Dale Macy, Andrei Rakitin, Courtney Mankus
-
Publication number: 20150064198Abstract: The invention is directed to compositions and methods for generating or enhancing the immune system of a patient against infection by a pathogen, and in particular MTB. Compositions of the invention contain one or more non-naturally occurring antigens that generate an effective cellular or humoral immune response to MTB and/or antibodies that are specifically reactive to mycolic acid or to the surface of MTB. The greater activity of the immune system generated by a vaccine of the invention involve an conjugation of peptides to increase in the generation of memory T cells that provide for a greater and/or longer lived or extended response to an MTB infection. Preferably a response involves an increased generation of antibodies that enhance immunity against MTB infection and promote an enhanced phagocytic response.Type: ApplicationFiled: August 29, 2014Publication date: March 5, 2015Inventors: Gerald W. Fischer, Luke T. Daum, Clara Jebet Sei
-
Publication number: 20150030600Abstract: The present disclosure provides antibodies that specifically bind to botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/C, BoNT/D, BoNT/E, BoNT/F, BoNT/G, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.Type: ApplicationFiled: August 31, 2011Publication date: January 29, 2015Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: James D. Marks, Yongfeng Fan, Jianlong Lou, Maria Consuelo Garcia Rodriguez, Shude Yan, Isin Nergiz Geren, Wenwu Zhai, Subhendu Chakraborti
-
Publication number: 20140356375Abstract: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.Type: ApplicationFiled: May 22, 2014Publication date: December 4, 2014Applicant: GENENTECH, INC.Inventors: Eric J. Brown, Martine Darwish, John Flygare, Wouter Hazenbos, Byoung Chul Lee, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen
-
Publication number: 20140356376Abstract: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.Type: ApplicationFiled: May 30, 2014Publication date: December 4, 2014Applicant: GENENTECH, INC.Inventors: Eric J. Brown, Martine Darwish, John Flygare, Wouter Hazenbos, Byoung Chul Lee, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen
-
Patent number: 8877191Abstract: The current invention provides high-affinity antibodies to the Pseudomonas aeruginosa PcrV protein that have reduced immunogenicity when administered to treat Pseudomonas aeruginosa infections.Type: GrantFiled: October 11, 2011Date of Patent: November 4, 2014Assignee: KaloBios Pharmaceuticals, Inc.Inventors: Christopher R. Bebbington, Kenneth Luehrsen, Geoffrey T. Yarranton, Mark Baer
-
Patent number: 8865479Abstract: Screening assays and methods of performing such assays are provided. In certain examples, the assays and methods may be designed to determine whether or not two or more species can associate with each other. In some examples, the assays and methods may be used to determine if a known antigen binds to an unknown monoclonal antibody.Type: GrantFiled: August 16, 2010Date of Patent: October 21, 2014Assignee: President and Fellows of Harvard CollegeInventors: J. Christopher Love, Hidde L. Ploegh, Jehnna Ronan
-
Publication number: 20140286960Abstract: Compositions and methods for the treatment or prevention of Staphyloccus aureus infection in a subject are provided. Antibody compositions comprising monoclonal antibodies to alpha-hemolysin protein are also provided. The methods provide administering a composition to the subject in an amount effective to reduce or eliminate or prevent relapse S. aureus bacterial infection and/or induce an immune response to Staphylococcus aureus alpha-hemolysin.Type: ApplicationFiled: July 27, 2012Publication date: September 25, 2014Applicant: Cangene CorporationInventors: Jody Berry, Laura Saward, Robyn Cassan, Xiaobing Han, Mohammad Javad Aman, Rajan P. Adhikari, Hatice Karauzum
-
Publication number: 20140273020Abstract: A system for detecting infectious agents in biological samples in real time that includes a sample to be tested for at least one specific infectious agent; and at least one biosensor, wherein the biosensor is operative to detect a specific infectious agent in the sample to be tested; wherein the biosensor emits a detectable signal when it reacts with the specific infectious agent; wherein the biosensor is a hybridoma cell that naturally expresses an endogenous anti-target antigen specific IgM; and wherein the hybridoma cell has been converted to a B cell receptor biosensor by introducing a detectable reporter gene into the cell.Type: ApplicationFiled: March 13, 2014Publication date: September 18, 2014Applicant: APPLIED BIOMOLECULAR TECHNOLOGIESInventors: Thomas J. ZUPANCIC, J.D. Kittle, Lingchun Zeng, Srikanth Vedamoorthy, Min Mo
-
Publication number: 20140275492Abstract: The present invention provides for methods of producing human monoclonal antibodies against a wide variety of antigens including bacterial and viral antigens, as well as tumor antigens, and various autoantigens. Also provided are the antibodies themselves, nucleic acids encoding such antibodies, cells producing such antibodies, and methods of using such antibodies for diagnostic assays and passive immunity against disease states such as infection and cancer.Type: ApplicationFiled: March 12, 2014Publication date: September 18, 2014Applicant: MUSC Foundation for Research DevelopmentInventors: Natalie SUTKOWSKI, Semyon Rubinchik
-
Patent number: 8835188Abstract: Screening assays and methods of performing such assays are provided. In certain examples, the assays and methods may be designed to determine whether or not two or more species can associate with each other. In some examples, the assays and methods may be used to determine if a known antigen binds to an unknown monoclonal antibody.Type: GrantFiled: August 6, 2013Date of Patent: September 16, 2014Assignee: Presidents and Fellows of Harvard CollegeInventors: J. Christopher Love, Hidde L. Ploegh, Jehnna Ronan
-
Patent number: 8835187Abstract: Screening assays and methods of performing such assays are provided. In certain examples, the assays and methods may be designed to determine whether or not two or more species can associate with each other. In some examples, the assays and methods may be used to determine if a known antigen binds to an unknown monoclonal antibody.Type: GrantFiled: August 6, 2013Date of Patent: September 16, 2014Assignee: Presidents and Fellows of Harvard CollegeInventors: J. Christopher Love, Hidde L. Ploegh, Jehnna Ronan
-
Publication number: 20140234339Abstract: The invention concerns a peptide or arrangement of peptides forming a Staphylococcus aureus epitope binding site comprising a first amino acid sequence and a second amino acid sequence, wherein the first amino acid sequence is at least 88% identical to sequence SEQ ID NO:1 and wherein the second amino acid sequence is at least 88% identical to sequence SEQ ID NO: 2.Type: ApplicationFiled: September 21, 2012Publication date: August 21, 2014Inventors: Knut Ohlsen, Udo Lorenz, Roland E. Kontermann
-
Publication number: 20140227257Abstract: The present invention relates to monoclonal antibodies that bind or neutralize anthrax protective antigen (PA) toxin. The invention provides such antibodies, fragments of such antibodies retaining anthrax PA toxin-binding ability, fully human or humanized antibodies retaining anthrax PA toxin-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.Type: ApplicationFiled: February 14, 2014Publication date: August 14, 2014Applicant: The USA, as represented by the Secretary, Department of Health and Human ServicesInventors: Zhaochun CHEN, Stephen H. LEPPLA, Mahtab MOAYERI, Suzanne U. EMERSON, Robert H. PURCELL
-
Patent number: 8772049Abstract: Screening assays and methods of performing such assays are provided. In certain examples, the assays and methods may be designed to determine whether or not two or more species can associate with each other. In some examples, the assays and methods may be used to determine if a known antigen binds to an unknown monoclonal antibody.Type: GrantFiled: August 6, 2013Date of Patent: July 8, 2014Assignee: President and Fellows of Harvard CollegeInventors: J. Christopher Love, Hidde L. Ploegh, Jehnna Ronan
-
Patent number: 8748173Abstract: The present invention provides monoclonal antibodies which are highly specific for Bacillus spores. Also provided are peptides derived from those monoclonal antibodies. Both the antibodies and peptides are highly specific and can discriminate between spores of potentially lethal organisms such as Bacillus anthracis and other harmless but closely related bacilli and provide a very powerful tool in the construction of detection instruments as counter measures.Type: GrantFiled: November 17, 2006Date of Patent: June 10, 2014Assignee: UAB Research FoundationInventor: John F. Kearney
-
Publication number: 20140120614Abstract: Antibodies that specifically bind to toxins of C. difficile, antigen binding portions thereof, and methods of making and using the antibodies and antigen binding portions thereof are provided herein.Type: ApplicationFiled: November 14, 2013Publication date: May 1, 2014Applicants: MEDAREX, L.L.C., UNIVERSITY OF MASSACHUSETTSInventors: Donna M. AMBROSINO, Gregory J. BABCOCK, Teresa BROERING, Robert GRAZIANO, Hector Javier HERNANDEZ, Israel LOWY, Robert MANDELL, Deborah MOLRINE, William D. THOMAS, JR., Hui-Fen ZHANG
-
Publication number: 20140099320Abstract: Described are human binding molecules specifically binding to enterococci and having killing activity against enterococci, nucleic acid molecules encoding the human binding molecules, compositions comprising the human binding molecules and methods of identifying or producing the molecules. The molecules can be used, for example, in the diagnosis, prophylaxis, and/or treatment of a condition resulting from Enterococcus.Type: ApplicationFiled: December 10, 2013Publication date: April 10, 2014Applicant: Crucell Holland B.V.Inventors: Mark Throsby, Robert A. Kramer, Cornelis A. de Kruif
-
Publication number: 20130287787Abstract: The present disclosure relates to monoclonal antibodies that bind poly-?-D-glutamic acid (?DPGA), which is present on the surface of Bacillus anthracis. The disclosure also provides chimeric forms of the monoclonal antibodies, humanized forms of the monoclonal antibodies, and fragments thereof, as well as nucleic acids encoding the antibodies and fragments thereof. Pharmaceutical compositions including such antibodies are also disclosed herein. The disclosure further provides prophylactic, therapeutic, and diagnostic methods of using the disclosed antibodies.Type: ApplicationFiled: July 5, 2013Publication date: October 31, 2013Inventors: Zhaochun Chen, Robert H. Purcell, Rachel Schneerson, Joanna Kubler-Kielb, Lily Z. Dai
-
Publication number: 20130243806Abstract: The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Some antibodies of the invention enhance opsonophagocytic killing and in vivo protection against bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.Type: ApplicationFiled: January 7, 2013Publication date: September 19, 2013Applicants: BETH ISRAEL DEACONESS MEDICAL CENTER, INC., THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: Gerald B. Pier, Casie Anne Kelly-Quintos, Lisa Cavacini, Marshall R. Posner
-
Publication number: 20130202618Abstract: Provided herein are reagents, compositions, and therapies with which to treat Clostridium difficile infection and related disease conditions and pathologies, such as Clostridium difficile-associated diarrhea, resulting from infection by Clostridium difficile bacteria and the enterotoxins produced by these bacteria. In particular, antibodies or antigen-binding fragments thereof that bind specifically to toxin A and/or toxin B of C difficile and neutralize the activities of these toxins; compositions comprising such antibodies; and methods of using the antibodies and the compositions are provided.Type: ApplicationFiled: April 15, 2011Publication date: August 8, 2013Applicant: Progenics Pharmaceuticals, Inc.Inventors: Dangshe Ma, Kirsten Nagashima, Brian Kennedy, Gerald P. Donovan, Yun Kang, William C. Olson, Shankar Kumar, Naoya Tsurushita, Andre J. Marozsan, Albert Cupo
-
Patent number: 8501182Abstract: The present disclosure relates to monoclonal antibodies that bind poly-?-D-glutamic acid (?DPGA), which is present on the surface of Bacillus anthracis. The disclosure also provides chimeric forms of the monoclonal antibodies, humanized forms of the monoclonal antibodies, and fragments thereof, as well as nucleic acids encoding the antibodies and fragments thereof. Pharmaceutical compositions including such antibodies are also disclosed herein. The disclosure further provides prophylactic, therapeutic, and diagnostic methods of using the disclosed antibodies.Type: GrantFiled: November 19, 2009Date of Patent: August 6, 2013Assignee: The United States of America, as Represented by the Secretary of the Department of Health and Human ServicesInventors: Zhaochun Chen, Robert H. Purcell, Rachel Schneerson, Joanna Kubler-Kielb, Lily Z. Dai
-
Publication number: 20130164308Abstract: The present invention provides antagonizing antibodies that bind to S. aureus alpha-toxin. The invention further provides a method of obtaining such antibodies and antibody encoding nucleic acids. The invention further relates to therapeutic methods for use of these antibodies for the treatment and/or prevention of staphylococcal disease, including, for example, pneumonia, bacteremia, sepsis, eye infection, and abscess.Type: ApplicationFiled: December 18, 2012Publication date: June 27, 2013Inventor: RINAT NEUROSCIENCE CORP.
-
Publication number: 20130096282Abstract: Improved antibodies are provided selected from human, dual-specific, chimeric or humanized antibodies, wherein said human chimeric and humanized antibodies specifically bind to flagellin type A or type B of P. aeruginosa, and said dual-specific antibodies specifically binds to flagella type A and type B of Pseudomonas aeruginosa, and said antibodies are protective against infection caused by P. aeruginosa. These antibodies as well as pharmaceutical composition comprising them are useful for the treatment of indications caused by P. aeruginosa infection.Type: ApplicationFiled: March 1, 2011Publication date: April 18, 2013Applicant: LOSTAM BIOPHARMACEUTICALS LTDInventor: Lewis F. Neville
-
Publication number: 20130064851Abstract: The vaccine that is protective against pathogenic bacterial species, typically staphylococcal species, and including methods to prepare said vaccine and to culture pathogenic bacteria.Type: ApplicationFiled: November 12, 2012Publication date: March 14, 2013Applicant: VACCINE RESEARCH INTERNATIONAL PLCInventor: Vaccine Research International PLC
-
Patent number: 8383359Abstract: It is disclosed herein that isolated lymphocytes, such as human B-cells and CD4+ T-cell can be used to determine an amount of lymphocyte-associated anthrax lethal toxin activity present. Methods of using isolated lymphocytes to identify anthrax therapeutic agents and to determine the efficacy of a potential anthrax therapeutic are disclosed. Methods are also provided for diagnosing and treating anthrax infections.Type: GrantFiled: September 24, 2010Date of Patent: February 26, 2013Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: David M. Frucht, Hui Fang
-
Publication number: 20120315278Abstract: Described are human binding molecules specifically binding to enterococci and having killing activity against enterococci, nucleic acid molecules encoding the human binding molecules, compositions comprising the human binding molecules and methods of identifying or producing the human binding molecules. The molecules can be used in the diagnosis, prophylaxis, and/or treatment of a condition resulting from Enterococcus.Type: ApplicationFiled: July 16, 2012Publication date: December 13, 2012Inventors: Mark Throsby, Robert Arjen Kramer, Cornelis Adriaan De Kruif
-
Publication number: 20120288508Abstract: Antibodies that specifically bind to toxins of C. difficile, antigen binding portions thereof, and methods of making and using the antibodies and antigen binding portions thereof are provided herein.Type: ApplicationFiled: June 7, 2012Publication date: November 15, 2012Applicants: MEDAREX, INC., UNIVERSITY OF MASSACHUSETTSInventors: Donna AMBROSINO, Gregory J. BABCOCK, Teresa BROERING, Robert GRAZIANO, Hector Javier HERNANDEZ, Israel LOWY, Robert MANDELL, Deborah MOLRINE, William D. THOMAS, JR., Hui-Fen ZHANG
-
Publication number: 20120282274Abstract: The disclosure provides specific and sensitive anti-toxin B antibodies and fragments thereof suitable for diagnosing Clostridium difficile infection. The antibodies and fragments recognize an epitope in the C-terminal 250-amino-acid region of toxin B of C. difficile, including epitopes defined by protein repeat sequences in this region of toxin B. This disclosure also provides the toxin B-specific epitope in the C-terminal 250-amino-acid region of toxin B of C. difficile for use in vaccine development as well as in the treatment of CDI disease and in treatment of the relapse of CDI disease. Also provided are toxin B polypeptides lacking the cytotoxic domain useful in treating or preventing CDI disease. PCR-based diagnostic assays targeting the 750-nucleotide region at the 3? end of tcdB are also provided.Type: ApplicationFiled: November 22, 2010Publication date: November 8, 2012Applicant: NORTHSHORE UNIVERSITY HEALTH SYSTEM RESEARCH INSTITUTEInventors: Jian-Ping Jin, Lance R. Peterson
-
Patent number: 8268316Abstract: Disclosed is a monoclonal antibody having very high affinity to anthrax toxin and potent toxin-neutralizing activity. Also disclosed are a composition for neutralizing anthrax toxin comprising the antibody and a kit for detecting anthrax toxin.Type: GrantFiled: March 10, 2006Date of Patent: September 18, 2012Assignee: Aprogen, IncInventors: Hyo Jeong Hong, Kyung Soo Inn, Nam Kyu Lim, Jung Whan Kim, Keun Soo Kim, Sang Yoon Lee, Se Yeon Kim, Hyun Jung Kang, Mee Sook Oh
-
Publication number: 20120208270Abstract: The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Some antibodies of the invention enhance opsonophagocytic killing and in vivo protection against bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.Type: ApplicationFiled: December 22, 2011Publication date: August 16, 2012Applicants: BETH ISRAEL DEACONESS MEDICAL CENTER, INC., THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: Gerald B. Pier, Casie Anne Kelly-Quintos, Lisa Cavacini, Marshall R. Posner
-
Publication number: 20120201829Abstract: The present invention includes a human monoclonal antibody specific for the alpha-toxin of S. aureus, a hybridoma producing it, nucleic acids encoding it, and host cells transfected therewith. Further, the present invention includes methods for producing the monoclonal antibody. In addition, the present invention includes pharmaceutical compositions comprising at least one antibody or at least one nucleic acid encoding the antibody. Further, the present invention includes the use of the monoclonal antibody for treating or preventing abscess formation.Type: ApplicationFiled: August 10, 2010Publication date: August 9, 2012Inventors: Michael Rudolf, Holger Koch
-
Publication number: 20120196359Abstract: The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Some antibodies of the invention enhance opsonophagocytic killing and in vivo protection against bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.Type: ApplicationFiled: December 22, 2011Publication date: August 2, 2012Applicants: BETH ISRAEL DEACONESS MEDICAL CENTER, INC., THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: Gerald B. Pier, Casie Anne Kelly-Quintos, Lisa Cavacini, Marshall R. Posner
-
Publication number: 20120157665Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.Type: ApplicationFiled: November 28, 2011Publication date: June 21, 2012Inventors: TIM BEAUMONT, MARK J. KWAKKENBOS, ERIC J. BROWN, JOHN H. MORISAKI, WOUTER L.W. HAZENBOS, SANJEEV MARIATHASAN, KIMBERLY KAJIHARA, YI XIA
-
Publication number: 20120100151Abstract: The invention concerns antibodies or fragments thereof that are directed against a Staphylococcus aureus epitope.Type: ApplicationFiled: May 18, 2010Publication date: April 26, 2012Applicant: JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURGInventors: Knut Ohlsen, Udo Lorenz
-
Patent number: 8148499Abstract: The invention relates to a vaccine for the treatment of disease caused by Neisseria, the vaccine comprising one or more immunogenic components for Neisseria serogroups, as well as antibodies to the immunogenic components and methods of preventing and treating Neisseria infections. The immunogens are based on elements of the inner core lipopolysaccharide.Type: GrantFiled: February 14, 2011Date of Patent: April 3, 2012Assignee: Isis Innovation Ltd.Inventors: Joyce Susan Plested, Michael Paul Jennings, Margaret Ann Jaqueline Gidney, Andrew David Cox, James Clare Richards, Edward Richard Moxon
-
Publication number: 20120045457Abstract: The present invention relates to isolated nucleic acid molecules which encode an antigen from a nontypable Haemophilus influenzae (H. influenzae) species, a vector which comprises such nucleic acid molecule, and a host cell comprising such vector. Furthermore, the invention provides antigens from a nontypable Haemophilus influenzae species, as well as fragments and variants thereof, a process for producing such antigens, and a process for producing a cell, which expresses such antigen. More specifically such antigens are produced by or associated with bacterial infections caused by nontypable Haemophilus influenzae.Type: ApplicationFiled: February 15, 2010Publication date: February 23, 2012Applicant: INTERCELL AGInventors: Alexander Von Gabain, Eszter Nagy, Andreas Meinke, Sanja Selak, Markus Hanner, Margarita Smidt, Michaela Weissgram, Birgit Noiges, Stefan Seidel, Julia Bacher, Christina Satke, Wolfgang Schueler, Martin Oleksiewicz
-
Publication number: 20110318758Abstract: The present invention provides for methods of producing human monoclonal antibodies against a wide variety of antigens including bacterial and viral antigens, as well as tumor antigens, and various autoantigens. Also provided are the antibodies themselves, nucleic acids encoding such antibodies, cells producing such antibodies, and methods of using such antibodies for diagnostic assays and passive immunity against disease states such as infection and cancer.Type: ApplicationFiled: August 4, 2008Publication date: December 29, 2011Applicant: MUSC FOUNDATION FOR RESEARCH DEVELOPMENTInventors: Natalie Sutkowski, Semyon Rubinchik
-
Publication number: 20110275148Abstract: The present invention relates to the field of animal health and in particular to Lawsonia intracellularis. In particular, the invention relates to a method of diagnosing Lawsonia intracellularis infection and a diagnostic test kit using Lawsonia intracellularis-specific antibodies. The invention also relates to the use of the method or test kit for diagnosing Lawsonia intracellularis infections.Type: ApplicationFiled: July 19, 2011Publication date: November 10, 2011Applicant: BOEHRINGER INGELHEIM VETMEDICA GMBHInventor: Malik MERZA
-
Publication number: 20110268739Abstract: Described are human binding molecules specifically binding to enterococci and having killing activity against enterococci, nucleic acid molecules encoding the human binding molecules, compositions comprising the human binding molecules and methods of identifying or producing the human binding molecules. The human binding molecules can be used in the diagnosis, prophylaxis, and/or treatment of a condition resulting from Enterococcus.Type: ApplicationFiled: May 19, 2011Publication date: November 3, 2011Inventors: Mark Throsby, Robert Arjen Kramer, Cornelis Adriaan De Kruif
-
Publication number: 20110250202Abstract: The present invention provides PBP2a peptide antigens for generating antibodies against MRSA, and provides high-affinity binding agents that detect MRSA by selective immunoreactivity with PBP2a. The antibodies are useful in methods and systems for detecting MRSA, including biosensor systems, or as components of diagnostic or detection kits. The antibodies, in some embodiments, have therapeutic value against MRSA infection.Type: ApplicationFiled: May 7, 2009Publication date: October 13, 2011Applicant: Innovative Biosensors, Inc.Inventors: Colette Cote, Qiao-Xi Zheng, Venkatakrishna Shyamala, Tom Hazel
-
Patent number: 8025890Abstract: The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics.Type: GrantFiled: May 16, 2006Date of Patent: September 27, 2011Assignees: Novartis Vaccines and Diagnostics, Inc., J. Craig Venter InstituteInventors: John Telford, Vega Masignani, Maria Scarselli, Guido Grandi, Herve Tettelin, Claire Fraser
-
Publication number: 20110201787Abstract: The present invention relates to the field of animal health and in particular to Lawsonia intracellularis. In particular, the invention relates to a method of diagnosing Lawsonia intracellularis infection and a diagnostic test kit using Lawsonia intracellularis-specific antibodies. The invention also relates to the use of the method or test kit for diagnosing Lawsonia intracellularis infections.Type: ApplicationFiled: April 28, 2011Publication date: August 18, 2011Applicant: BOEHRINGER INGELHEIM VETMEDICA GMBHInventor: Malik MERZA
-
Publication number: 20110200614Abstract: The present invention is directed to diagnostic tools and therapies using antibodies to Bacillus anthracis. Specifically, the present invention is directed to a B. anthracis-specific monoclonal antibody that binds to the EA1 antigen (corresponding to the eag gene) of the S-layer (surface layer) of spores. This monoclonal antibody may be used in a variety of applications, including to specifically detect and diagnose B. anthracis. Preferably, antibodies are monoclonal and bind to a surface protein, such as EA1 protein, on the spores of B. anthracis, and not to spores of either B. cereus or B. thuringiensis. Antibodies can be incorporated into detection kits using, for example, colloidal particle based lateral flow detection system. Such detection kits can distinguish anthrax spores from non-pathogenic varieties of spores. In addition, the invention is directed to B.Type: ApplicationFiled: November 16, 2009Publication date: August 18, 2011Inventors: Beverly Lynn Mangold, Jennifer Lynn Aldrich, Thomas W. O'Brien
-
Publication number: 20110201786Abstract: The present invention relates to the field of animal health and in particular to Lawsonia intracellularis. In particular, the invention relates to a method of diagnosing Lawsonia intracellularis infection and a diagnostic test kit using Lawsonia intracellularis-specific antibodies. The invention also relates to the use of the method or test kit for diagnosing Lawsonia intracellularis infections.Type: ApplicationFiled: April 28, 2011Publication date: August 18, 2011Applicant: BOEHRINGER INGELHEIM VETMEDICA GMBHInventor: Malik MERZA
-
Publication number: 20110201788Abstract: The present invention relates to the field of animal health and in particular to Lawsonia intracellularis. In particular, the invention relates to a method of diagnosing Lawsonia intracellularis infection and a diagnostic test kit using Lawsonia intracellularis-specific antibodies. The invention also relates to the use of the method or test kit for diagnosing Lawsonia intracellularis infections.Type: ApplicationFiled: April 28, 2011Publication date: August 18, 2011Applicant: BOEHRINGER INGELHEIM VETMEDICA GMBHInventor: Malik MERZA
-
Publication number: 20110177087Abstract: The invention described herein provides for human antibodies produced in non-human animals that specifically bind to lipopolysaccharide (LPS) from strains Fisher Devlin (International Serogroups) It-2 (011), It-3 (02), It-4 (01), It-5 (010), It-6 (07), PA01 (05), 170003 (02), IATS016 (02/05), and 170006 (02). The invention further provides methods for making the antibodies in a non-human animal, expression of the antibodies in cell lines including hybridomas and recombinant host cell systems. Also provided are kits and pharmaceutical compositions comprising the antibodies and methods of treating or preventing pseudomonas infection by administering to a patient the pharmaceutical compositions described herein.Type: ApplicationFiled: July 13, 2010Publication date: July 21, 2011Inventor: John R. Schreiber
-
Publication number: 20110171234Abstract: The invention relates to a vaccine for the treatment of disease caused by Neisseria, the vaccine comprising o more immunogenic components for Neisseria serogroups, as well as antibodies to the immunogenic components and m preventing and treating Neisseria infections.Type: ApplicationFiled: February 14, 2011Publication date: July 14, 2011Applicant: Isis Innovation LimitedInventors: Joyce Susan Plested, Michael Paul Jennings, Margaret Ann Jaqueline Gidney, Andrew David Cox, James Clare Richards, Edward Richard Moxon
-
Publication number: 20110171237Abstract: The present invention relates to antigenic polypeptides expressed by pathogenic microbes, including antigenic polypeptides encoded by the nucleic acid sequence of FIG. 1, vaccines comprising the antigenic polypeptides and therapeutic antibodies directed to the antigenic polypeptides.Type: ApplicationFiled: April 23, 2010Publication date: July 14, 2011Applicant: ABSYNTH BIOLOGICS LTD.Inventor: Simon J. FOSTER
-
Publication number: 20110150896Abstract: Provided is an effective means for therapy of infection, particularly infection with Pseudomonas aeruginosa. Provided are a monoclonal antibody against PcrV or a part thereof, and a pharmaceutical composition containing the same as an active ingredient. Concretely, monoclonal antibody of the present invention has excellent inhibiting activity on cytotoxicity with respect to a target cell of Pseudomonas aeruginosa. Also, the monoclonal antibody of the present invention has high affinity with PcrV.Type: ApplicationFiled: January 8, 2009Publication date: June 23, 2011Applicant: Shionogi & Co., Ltd.Inventors: Yoshito Numata, Yoshinori Yamano, Takafumi Sato, Toshinaga Tsuji